Fifth Circuit Stay Reinstates Nationwide In-Person Dispensing Requirement for Mifepristone - Reed Smith LLP
The Fifth Circuit has reinstated the in-person dispensing requirement for mifepristone nationwide, reversing a previous ruling that had suspended it.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 11, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All healthcare providers, pharmacies, and distributors involved in dispensing mifepristone in the United States. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate, as the stay is reinstated nationwide.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The in-person dispensing requirement for mifepristone is now back in effect nationwide, meaning patients must receive the drug directly from a certified prescriber or healthcare setting, rather than via telehealth or mail-order.
Who it affects
All healthcare providers, pharmacies, and distributors involved in dispensing mifepristone in the United States.
What you must do
Review and adjust dispensing protocols to ensure compliance with the reinstated in-person requirement, including verifying that all mifepristone prescriptions are dispensed in person.
Deadline
Immediate, as the stay is reinstated nationwide.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.